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Abstract
Background: Genetic Hypophosphatemic Rickets (HR) is a group of diseases characterized by renal phosphate
wasting with inappropriately low or normal 1,25-dihydroxyvitamin D3 (1,25(OH)2D) serum levels. The most common
form of HR is X-linked dominant HR (XLHR) which is caused by inactivating mutations in the PHEX gene. The
purpose of this study was to perform genetic diagnosis in a cohort of patients with clinical diagnosis of HR, to
perform genotype-phenotype correlations of those patients and to compare our data with other HR cohort studies.
Methods: Forty three affected individuals from 36 non related families were analyzed. For the genetic analysis, the
PHEX gene was sequenced in all of the patients and in 13 cases the study was complemented by mRNA
sequencing and Multiple Ligation Probe Assay. For the genotype-phenotype correlation study, the clinical and
biochemical phenotype of the patients was compared with the type of mutation, which was grouped into clearly
deleterious or likely causative, using the Mann-Whitney and Fisher’s exact test.
Results: Mutations in the PHEX gene were identified in all the patients thus confirming an XLHR. Thirty four
different mutations were found distributed throughout the gene with higher density at the 3’ end. The majority of
the mutations were novel (69.4%), most of them resulted in a truncated PHEX protein (83.3%) and were family
specific (88.9%). Tubular reabsorption of phosphate (TRP) and 1,25(OH)2D serum levels were significantly lower in
patients carrying clearly deleterious mutations than in patients carrying likely causative ones (61.39 ± 19.76 vs.
80.14 ± 8.80%, p = 0.028 and 40.93 ± 30.73 vs. 78.46 ± 36.27 pg/ml, p = 0.013).
Conclusions: PHEX gene mutations were found in all the HR cases analyzed, which was in contrast with other
cohort studies. Patients with clearly deleterious PHEX mutations had lower TRP and 1,25(OH)2D levels suggesting
that the PHEX type of mutation might predict the XLHR phenotype severity.
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Background
Genetic Hypophosphatemic Rickets (HR) is a group of
diseases characterized by renal phosphate wasting, with
inappropriately low or normal serum 1,25-dihydroxyvi-
tamin D3 (1,25(OH)2D) levels, causing growth retarda-
tion, rickets and osteomalacia. The most common form
is X-linked dominant hypophosphatemic rickets (XLHR,
OMIM 307800) with an incidence of 1/20,000 [1].
XLHR is caused by inactivating mutations in the PHEX
gene (Phosphate Regulating Gene with Homologies to
Endopeptidases on the × chromosome) which is located
in Xp22.1-22.2 [2]. Singular cases are autosomal forms
with a much lesser incidence. These include autosomal
dominant HR, caused by mutations in the fibroblast
growth factor 23 gene (FGF23) (ADHR, OMIM 193100)
[3] and autosomal recessive HR caused by mutations in
dentin matrix protein 1 gene (DMP1) (ARHR1, OMIM
241520) [4] and mutations in ectonucleotide pyropho-
sphatase/phosphodiesterase-1 gene (ENPP1) (ARHR2,
OMIM 613312) [5,6]. Excess action of fibroblast growth
factor 23 (FGF23) underlies the pathogenesis of these
hypophosphatemic diseases. FGF23 acts mainly as a
phosphaturic factor [7] and also reduces the 1,25(OH)
2D production [8]. Although initially FGF23 was sug-
gested as a substrate for PHEX, further studies failed to
confirm this [9,10]. On the other hand, PHEX binds to
MEPE C-terminal ASARM peptide and neutralizes its
biological activity as an inhibitor of mineralization
[11,12].
The PHEX gene consists of 22 short exons with huge
intronic regions. The coding region spans 2,250 bp and
encodes for a 749-aminoacid transmembrane endopepti-
dase that belongs to the type II integral membrane zinc-
dependent endopeptidase family [13].
Structurally, PHEX has a small aminoterminal intra-
cellular tail, a short transmembrane domain and a large
carboxyterminal extracellular domain with the catalytic
and zinc-binding sites [14,15]. PHEX is mainly
expressed in osteoblast, osteocytes and odontoblast
[16,17].
More than 250 different PHEX mutations have been
described to date, including nonsense (17-19%), mis-
sense (21-22%), deletions (24-30%), insertions (11-12%)
and splice mutations (18-24%) unevenly distributed
along the PHEX gene with three regions with high
mutation density [18-20].
The main purpose of this study was to perform
genetic diagnosis in a cohort of patients with clinical
diagnosis of HR. The second objective was to asses any
possible genotype-phenotype correlation. The third was
to review and compare the prevalence and distribution
of PHEX mutations in the present study with previously
published HR cohort studies.
Methods
Patient’s phenotype
A total of 46 patients clinically diagnosed with HR and
one pre-symptomatic infant (11 males and 35 females)
belonging to 36 unrelated families were studied. The
parents of the children patients or the patient itself,
who had given the informed consent to participate in
the study, were referred to the laboratory for genetic
analysis from different Spanish and Portuguese hospi-
tals. Forty six non affected family members were also
analyzed. The age at diagnosis of the 36 probands as
well as the clinical and biochemical features are sum-
marized in table 1. Samples were collected after 12
hours of fasting and the assessment of phosphate
serum levels (P) (Normal values: adolescents and
adults > 2.5, infants 4.8-7.4; toddlers 4.5-5.8; children
3.5-5.5 mg/dl [21]), tubular reabsorption of phosphate
(TRP), 25 hydroxy vitamin D (25(OH)D), 1,25 dihy-
droxyvitamin D (1,25(OH)2D), parathyroid hormone
(PTH) and alkaline phosphatase (AP) were performed
in each referring hospital. All the measurements were
at the time of diagnosis and prior to any treatment.
The severity of skeletal deformities was qualitatively
assessed by the physician into: mild: patients with null
or subtle genu varum, moderate: genu varum and/or
femur deformities not requiring correcting surgery
and severe: genu varum and/or femur deformities
requiring correcting surgery. The patient’s height SDS
[22], at the time of diagnosis and the presence of
nephrocalcinosis and/or hyperparathyroidism before
and after treatment were also recorded. It was impos-
sible to get detailed phenotypic data from some
patients in spite of a clinical diagnosis of HR for all of
them.
All the procedures followed were in accordance with
the local legislation and with the current Helsinki
Declaration.
Mutational analysis of the PHEX gene
DNA isolation from peripheral blood leukocytes was car-
ried out in the Chemagic Magnetic Separation Module I
(Chemagen, Baesweiler, Germany) following the manufac-
turer’s instructions. RNA was obtained from peripheral
blood using the RNeasy mini Kit (Qiagen, Valencia CA,
USA). For the detection of punctual mutations, the 22
exons and intron exon boundaries that comprise the
PHEX gene were independently amplified by PCR using
primers already described [23]. The complete PHEX cod-
ing region was amplified by RT-PCR in three overlapping
fragments with the following pairs of primers: 5’ ATG-
GAAGCAGAAACAGGGAG 3’ and 5’ GCTGTATTGAC-
CACGAAACG 3’, 5’ AGAAAGCCAAAATCCTTTAT 3’
and 5’ TTGGTGGATGCACTGTAGAA 3’ and 5’ GCCG
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ACTACTTTGGCAACGT 3’ and 5’ CTACCAGAGTCG
GCAGGAGT 3’. The PCR products were purified and
both strands were subjected to cycle sequencing using the
BigDye terminator kit and run in the 3730 × l DNA Ana-
lyzer (Applied Biosystems, Foster City, CA, USA). The
obtained electropherograms were analyzed with the Sta-
den Package V.1.6 (http://www.staden.sourceforge.net).
For the detection of exons deletions or duplications Multi-
ple Ligation Dependent Probe Amplification (MLPA) was
used following the manufacturer’s recommendations
(SALSA MLPA Kit P223 PHEX, Versión.01. MRC-Hol-
land, Amsterdam, Netherlands). DNA sequence
abnormalities were analyzed in the parents and other rela-
tives of the proband when available.
All the mutations identified in this study were entered
into the PHEX mutation database [18] (http://www.
phexdb.mcgill.ca). A novel missense variation was con-
sidered a real mutation and not a genetic polymorphism
when it was not found in 130 control chromosomes (65
control females).
Splicing prediction
Splicing prediction was performed with a module (Ala-
mut Interactive Biosoftware, Rouen, France) which is
Table 1 Phenotype characteristic of studied HR patients
Pr G AD BPS H P (mg/dl) TRP (%) 25(OH)D (ng/mL) 1,25(OH)2D (pg/ml) PTH (pg/mL) AP (UI/l) N HP
1 F 1 y 3 m Mild 2.9 28 87 1531
2 F 3 y Sev -2.71 2.3 60 48 558 N Y
3 M 9 y Sev -3.38 2.3 56.4 13.2 21 766 N N
4 M 1 y 4 m Sev -2.34 2.8 78.4 29.7 73 28 378 N N
5 F 1 y 4 m 2.7 25.3 12 Y
6 F 1 y 10 m Mod -4.06 2.1 N N
7 M 2 y 3 m Mod -3.2 2.9 76 175.2 79 1786 Y N
8 M 1 y 5 m Mod N N
9 M 2 y 6 m Mod -2.01 2.4 80 79 38.2 18 584 Y Y
10 F 1 y 6 m Mod -2.05 2.7 91 52 791 N N
11 F 4 m Mild 0.88 4 89 41 75 75 1755 N N
12 F 1 y 6 m Sev -3.35 2.1 32 27.5 16 68 1646 N N
13 F 7 y Sev -2.24 2.8 58.2 21.9 49 1699 N Y
14 F 3 y
15 F
16 F 4 y 6 m Mod -1.97 2.5 52 28 29 991 N Y
17 F 4 y 7 m Sev -4.86 16 28 25 755 N Y
18 F 1 y 7 m Mod -3.11 3.1 82.3 43 60 60 934 N N
19 F 14 y Sev -3.84 66 37.5 42 534 N N
20 F 1 y 7 m Mild -2.53 2.2 71 30.1 129 66.7 597 N Y
21 F 2 y 8 m Sev -2.97 2.5 78 28 53 66 1020 N N
22 F 4 y Sev -1.65 2.1 83 23 448 Y N
23 M 3 y 2 m Mod -5.47 2.7 23 Y BT
24 M 1 y 2 m Sev -2.26 2.0 59 30.1 57 1010 Y Y
25 F 2 y 6 m Sev -2 2.7 46 45.2 53.4 48 528 N Y
26 F 1 y 4 m Mild 0.62 2.5 73 76 60 1249 N N
27 M 3 y 2 m Mod -3.23 2.6 77.6 30 41 43 1389 N N
28 F 2 y 6 m Mild -2.56 2.8 33 220 N N
29 F 1 y 6 m Mod -3.1 2.4 66 54.2 39.8 58 856 N N
30 F 4 y 10 m Mod -1.84 2.1 85 18 147 78 1513 N BT
31 F
32 F 5 y Sev -3.31 3.1 59.2 32 52.3 1110 N Y
33 M 5 m Sev 0.64 3.7 62.3 6.6 13.8 22 1204 N N
34 F 3 y Mild -4.37 2.2 N N
35 F 3 y 8 m Mod -2.3 2.6 75 39 14 49 1109 N N
36 F 4 y 5 m Sev -1.95 3.7 86.7 31 56.3 49 470 N N
Pr proband, G gender, AD age at diagnosis, BPS bone phenotype severity (Mod moderate, Sev severe), H height SDS, P phosphate serum levels, TRP tubular
reabsorption of phosphate, 1,25(OH)2D 1,25 dihydroxi vitamin D, 25(OH)D 25 hydroxy vitamin D, PTH parathyroid hormone at diagnosis, AP alkaline phosphatase,
N nephrocalcinosis after treatment, HP hyperparathyroidism (Y postreatment, BT before treatment, N no)
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based in four different algorithms: SpliceSiteFinder,
MaxEntScan, NNSplice and GVGD
Genotype-phenotype correlation
The data considered for the genotype-phenotype corre-
lation in the probands were: gender, severity of skeletal
deformities, height SDS, TRP and serum levels of P, 25
(OH)D, 1,25(OH)2D, PTH and AP before treatment.
Presence of nephrocalcinosis and/or hyperparathyroid-
ism before and after treatment was also recorded even
though treatment regimens varied across the clinical
sites according to local practices. Unfortunately, no phe-
notypic data were available for some patients.
The mutations detected in the patients were classified
into two groups: One group of certain deleterious muta-
tions that resulted in premature stop codons, which
included nonsense mutations, insertion or deletion and
splice site mutations, and a second group of plausible
causative mutations, which included missense mutations
and an in frame three nucleotide deletion.
Statistical analysis was performed with the R-free soft-
ware environment for statistical computing and gra-
phics. The non-parametric Mann-Whitney test was used
to compare biochemical levels and height SDS with the
specific type of PHEX mutation. The Fisher’s exact test
was used to compare the presence of nephrocalcinosis,
hyperparathyroidism and severity of skeletal involvement
with the specific type of PHEX mutation.
Results
The underlying PHEX mutation was identified in all the
36 probands studied and in their affected family mem-
bers. One two month old infant belonging to an affected
pedigree was also genetically diagnosed prior to clinical
diagnosis. Thirty cases (83.3%) appeared to be sporadic
because there was no family history of the disease; this
group included a pair of monozygotic twins. Only the
parents of 21 probands were available for analysis and
they were not mutation carriers, which suggested that
the mutations had occurred de novo. Nevertheless, par-
ental mosaicism could not be totally excluded. Six of
the probands were familial cases (16.7%) with at least
the mother and one child being clinically affected. In
these cases, the identified mutation cosegregated with
the disease and was not found in the non affected family
members.
PHEX mutations
In this study, thirty four different PHEX gene mutations
were identified. Only two mutations were recurrent in
the studied families: the nonsense mutations p.Arg549X,
which appeared in two independent cases, and p.
Arg702X, which appeared both in one sporadic and in
one familial case. All the other mutations were family
specific (Table 2). The majority of the mutations found
were novel (69.4%) while only nine had been previously
described (30.5%) [13,23-26]. Most of the mutations
(83.3%) resulted in premature termination codons and
therefore in truncated PHEX proteins. These included:
nine different nonsense mutations, four of which had
been previously described and five were novel. Seven
deletions, a pair of two nucleotides deletions and five
gross deletions of one single exon or of a group of con-
tiguous exons, which were also novel. One insertion of a
single nucleotide, four duplications of one to four
nucleotides and one duplication from an unknown site
somewhere in intron 2 to somewhere in intron 3 were
also found. This last mutation was not detected by
genomic DNA sequencing and only became evident by
sequencing the RT-PCR product, where exon 3
appeared duplicated, and was thereafter confirmed by
MPLA analysis. Seven additional mutations were found
to affect the normal splicing and resulted in premature
stop codons; six of them were novel. The mutation
c.1965+1G > A had been previously described though
its effect on the splicing had not been biologically con-
firmed. In this study, the presence of a pseudoexon
which consisted in 59 bp corresponding to intron 19 in
the mRNA was proven. Another mutation, c.1654G > A,
resulted in a pseudoexon of 74 bp from intron 15. No
mRNA of sufficient quality was available from other
splicing mutations carriers and the effect of the muta-
tions could not be biologically proven. In those cases,
the effect of the mutations was predicted by bioinforma-
tical algorithms (see Materials and Methods). The
c.591A > G variant in exon 5 is a silent mutation which
encodes for the residue 197 glutamine: however, the
theoretical splicing prediction indicated an aberrant
splice donor site. This mutation appeared de novo in the
affected patient. A small number of missense mutations
were found, (13.8%), three of them were already
described and two were novel, which were confirmed as
de novo mutations. Finally, there was one in frame dele-
tion, c.1936_1938del that resulted in an mRNA lacking
codon 646. All the mutations identified in this series
were distributed along the PHEX gene although there
was a higher mutation density from exon 13 to 22 (Fig-
ure 1).
Genotype-phenotype correlation
The study of any possible correlation between the
patient’s phenotype and the type of mutation showed
that TRP values were significantly lower in patients
with clearly deleterious mutations than in patients with
plausible causative mutations (61.39 ± 19.76 vs. 80.14
± 8.80%, p = 0.028). Likewise, 1,25(OH)2D serum levels
were significantly lower in patients with deleterious
mutations in comparison with the other group of
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patients (40.93 ± 30.73 vs. 78.46 ± 36.27 pg/ml, p =
0.013). On the other hand, no significant correlations
were observed between the mutation type and height
SDS, serum phosphate, 25(OH)D, PTH or alkaline
phosphatase levels at diagnosis (Table 3). Six patients
(16%) from this cohort developed nephrocalcinosis and
all of them were carriers of deleterious mutations.
Unfortunately, the non existence of a standard treat-
ment and the small number of patients with this com-
plication prevents the evaluation of any correlation
between treatment regimen and appearance of
nephrocalcinosis.
Eleven patients presented hyperparathyroidism (three
before treatment) and ten of them were deleterious
mutation carriers. Nevertheless, no significant correla-
tion was observed between the mutation type and the
PTH levels at diagnosis. No significant correlation was
observed either between the mutation type and the
bone phenotype. It should be taken into account that
some patients were diagnosed at later ages, which
could have worsened their bone phenotype. Finally,
phenotype comparison between males and females
independent of the mutation type, showed that females
developed less nephrocalcinosis than males (p = 0.03).
Table 2 PHEX mutations found in this study
Pr Inh E/I cDNA* Protein** Mutation Type PHEXdb ID
1 F E 01 c.77_78del p.Phe26CysfsX24 Deletion 261
2 S E 03 c.188-?_349+?del p.? Del (> 0.16 Kb) 264
3 F E 03 c.188-?_349+?dup p.Ala63_Lys116dup Dup (E3) 262
4 F E 03 c.212A > T p.Asn71Ile Missense 263
5 S E 04 c.395_398dup p.Gln133HisfsX14 Duplication 265
6 S I 04 c.436+3G > C p.? Splicing 266
7 S E 05 c.565C > T p.Gln189X Nonsense 171 [24]
8 S E 05 c.591A > G p. = Splicing 267
9 F E 06 c.682dup p.Ser228PhefsX10 Duplication 268
10 F E 07 c.750C > G p.Tyr250X Nonsense 269
11 S E 07 c.784G > C p.Ala262Pro Missense 270
12 S E 08 c.897_898del p.Lys299AsnfsX5 Deletion 271
13 S E 10 c.1105A > T p.Arg369X Nonsense 272
14 S I 10 c.1173+1G > A p.? Splicing 273
15 S E 13-15 c.1405-?-1645+? p? Del (> 22 Kb) 274
16 S E 13-22 c.1412-?-2250+? p.Ile495TrpfsX20 Del (> 80 Kb) 275
17 S I 13 c.1482+4delA p.? Splicing 276
18 S E 14 c.1529G > C p.Arg510Pro Missense 133 [25]
19 S E 14 c.1543C > T p.Gln515X Nonsense 277
20 S E 15 c.1639C > T p.Gln547X Nonsense 278
21 S E 15 c.1645C > T p.Arg549X Nonsense 13 [23]
22 S E 15 c.1645C > T p.Arg549X Nonsense 13 [23]
23 S I 15 c.1645+1G > A p.Phe550fsX21 Splicing 155 [26]
24 S E 16-22 c.1646-?-2250+? p.? Del (> 34 Kb) 279
25 S E 17-20 c.1701-?_2070+? p.? Del (> 29 Kb) 280
26 S E 17 c.1735G > A p.Gly579Arg Missense 90 [23]
27 S I 17 c.1768+174_1768+177dupTAAG p.? Splicing 281
28 S E 18 c.1825G > T p.Glu609X Nonsense 282
29 S E 19 c.1936_1938del p.Asp646del Del (in frame) 283
30 S E 19 c.1952G > C p.Arg651Pro Missense 76 [13]
31 S I 19 c.1965+1G > A p.? Splicing 62 [23]
32 S E 21 c.2104C > T p.Arg702X Nonsense 16 [23]
33 F E 21 c.2104C > T p.Arg702X Nonsense 16 [23]
34 S E 21 c.2138_2139dupCT p.Gln714LeufsX27 Duplication 284
35 S E 22 c.2168dupA p.Asn723LysfsX3 Duplication 285
36 S E 22 c.2239C > T p.Arg747X Nonsense 17 [13]
Pr proband, Inh inheritance, (F familial, S sporadic), E/I Exon/Intron, *[GenBank ID: NM_000444.4], **[Swiss-Prot: P78562], PHEXdb ID identification in the PHEX
mutation database [18] in bold novel mutations
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No other significant differences were found between
genders.
Discussion
In this report, the molecular genetic analysis performed
in 46 individuals of Iberian ancestry and clinically diag-
nosed with HR as well as the genotype-phenotype corre-
lation in the probands is presented. The causative PHEX
mutation was identified both in all the affected indivi-
duals from the familial cases (15) as well as in all the
sporadic ones (31), thus, confirming a XLHR in the
entire cohort. The results obtained confirmed that
PHEX is the most responsible gene for the HR pheno-
type in the majority of patients, and that mutations in
genes such as FGF23, DMP1 or ENPP1 must be very
scarce in our population. In fact, searching for muta-
tions in other genes was not necessary for the genetic
diagnosis in this series.
This study shows, to our knowledge, the highest
mutation detection rate reported so far in HR patients.
The percentage of detected mutations in other cohort
studies ranged from 45% to 87% [13,20,23,26-29]. The
high rate of mutation detection in the present study can
be explained by several reasons. Firstly, it could be due
to the careful clinical and biochemical selection of
patients before referring their samples for genetic
analysis. Also, the methodology used for the mutation
detection could be an explanation. Our approach detects
punctual mutations by sequencing but also large dele-
tions or duplications by MLPA analysis. Conversely,
researchers of other studies, lack a method for detection
of single or contiguous exons deletions. The fact that
such type of mutations were not observed in some stu-
dies despite a PHEX mutation detection rate of 87% in
familial and 72% in sporadic cases, underlies the impact
of the methodology used. That type of mutations repre-
sented 13.9% in our study, with 100% mutation detec-
tion rate. Furthermore, it has been pointed out that
those single or contiguous exons deletions may account
for up to 19% of PHEX mutated alleles [30]. Finally, dif-
ferences in the genetic background between the series
published cannot be ruled out. Moreover, in other stu-
dies, the mutations detected in familial cases were
higher than in sporadic ones, whereas we observed the
same mutation rate in both groups.
All types of mutations were found in this cohort and
the majority of them were novel. This was in agreement
with other cohort studies where most of the mutations
observed were specific to each family and the minority
of them was recurrent. Nonsense mutations represented
a 30.5% of the causative mutations found in this study.
Five were novel and four had been previously described,
Figure 1 Schematic representation of the PHEX gene with the localization of the mutations found in this study. Horizontal lines
represent the extention of gross deletions. GenBank ID: NM_000444.4
Table 3 Genotype-phenotype correlation at diagnosis
Type of
mutation
AD H P (mg/dl) TRP (%) 1.25(OH)2D
(pg/ml)
25(OH)D (ng/
ml)
PTH (pg/ml) ALP (UI/l)
Deleterious
(n = 30)
41.18 ± 33.27
(n = 28)
-2.81 ± 1.23
(n = 24)
2.61 ± 0.45
(n = 24)
61.39 ± 19.76
(n = 22)
40.93 ± 30.73
(n = 16)
41.79 ± 42.05
(n = 14)
45.35 ± 17.61
(n = 20)
943.00 ± 451.18
(n = 22)
Plausible
(n = 6)
21.83 ± 18.53
(n = 6)
-1.48 ± 1.80
(n = 6)
2.81 ± 0.67
(n = 6)
80.14 ± 8.80
(n = 5)
78.46 ± 36.27
(n = 6)
43.15 ± 19.13
(n = 6)
59.83 ± 17.76
(n = 6)
1114.16 ± 495.77
(n = 6)
P values 0.08 0.11 0.53 0.028 0.013 0.30 0.06 0.48
AD age at diagnosis (months), H height SDS, P phosphate serum levels, TRP tubular reabsorption of phosphate, 1,25(OH)2D 1,25 dihydroxi vitamin D, 25(OH)D 25
hydroxy vitamin D, PTH parathyroid hormone, ALP alkaline phosphatase. All parameters were assesed at diagnosis
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two of them were recurrent in our study. These muta-
tions resulted in truncated proteins which lack either a
large region with the highly conserved metallopeptidase
domain or just the final three residues, like the p.
Arg747X mutation. The PHEX arginine residue 747 has
been shown to be involved in substrate interaction in
the homologous protein neprilysin [31]. The nonsense
mediated decay, (which selectively eliminates mRNAs
containing premature stop codons), is an accepted med-
iator mechanism in the deleterious process of the non-
sense mutations [32]. In fact, we were not able to detect
any mRNA corresponding to the nonsense mutated
alleles by RT-PCR. Deletions represent a 22.2% of the
mutations in this series and all of them were novel: Two
small frameshift deletions in exon 1 and 8, and four
large deletions which involved several contiguous exons,
mainly exons 13 to 22. These mutations were detected
by MLPA analysis which was used when no punctual
mutation was detected by gene sequencing. In male car-
riers the deletions were confirmed by the absence of
PCR product of the corresponding exons. Two addi-
tional in frame deletions were found. A deletion that
included the complete exon 3, which would result in a
PHEX protein lacking 53 residues of the peptidase M13
and which was considered as deleterious for the geno-
type-phenotype correlation analysis. A triplet deletion
that would result in a protein lacking the aspartic acid
646, which was considered as plausible causative muta-
tion for genotype-phenotype correlation study. Duplica-
tions accounted for 13.8% of the mutations. Four were
small frameshift duplications and one was a gross dupli-
cation that involved the complete exon 3. This last one
was evident by RT-PCR and also by MLPA analysis. It is
possible that during meiosis a chromatid misalignment
occurred and resulted in either deletion or duplication
of exon 3 because of more than 85% sequence homology
between three stretches of intron 2 and 3. Splicing
mutations accounted for 19.4% of the cases. Aberrant
mRNA was detected in two of the patients and although
no RNA of sufficient quality was available from the rest
of them, the effect of the mutation was deduced based
on splicing prediction algorithms and cosegregation of
the mutation with the disease phenotype. The synon-
ymous mutation c.591A > G created an abnormal splice
donor site in the middle of exon 5. Only five missense
mutations (13.8%) were found: p.Arg510Pro, p.
Gly579Arg and p.Arg651Pro which had been already
described associated with the disease [13,20,23,29]. Even
more, the p.Gly579Arg mutant protein was shown to be
sensitive to endoglycosidase H digestion and to remain
trapped in the endoplasmic reticulum in contrast to the
wild type PHEX, thus providing a mechanism for loss of
PHEX function [33]. And two missense mutations not
previously described: p.Asn71Ile and p.Ala262Pro that
are very likely pathogenic. Both had appeared de novo in
the affected individuals and they were not found in 130
normal chromosomes. These mutations resulted in the
substitution of highly conserved PHEX aminoacids in
different species (Figure 2), which suggested that both
residues are important for protein function and that the
mutations are probably damaging.
The 36 different mutations found in our study were
distributed along the gene and affected almost all exons
or their adjacent introns. However, the main density of
the mutations was located at the end of the gene, which
is one of the three described regions with high mutation
density [20]. When comparing the distribution of our
mutations with the mutations from the PHEX mutation
database [18], a lower mutation density was observed in
the first and second part of the gene in our study (Fig-
ure 3).
For the genotype-phenotype correlation analysis, the
mutations were grouped based on their predicted effect
rather than on their localization as it seemed a better
approach in other investigations [26,34,35]. One group
comprised all the mutations which were very likely dele-
terious because they would result in a truncated PHEX
protein. This group included nonsense mutations,
Figure 2 PHEX protein sequence alignment in different species. N residue asparagine 71 and A alanine 262, involved in the p.Asn71Ile and
p.Ala262Pro mutations respectively.
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frameshift mutations due to small duplications and dele-
tions, large duplications and deletions and splicing
mutations. The second group included missense muta-
tions and a triplet deletion which might result in a
PHEX protein with reduced but not totally abolished
activity. Indeed, significant correlation between TRP and
1,25(OH)2D l serum levels with the mutation type was
found. As could be expected, patients with deleterious
mutations had lower TRP and lower 1,25(OH)2D levels.
Both might be the consequence of more active FGF23.
Even so, we are conscious that the sample is small, that
some parameters may have influenced the results and
that larger series of patients should be analyzed to con-
firm our results. No additional statistical genotype-phe-
notype correlation was observed with other parameters.
The mildest phenotype was shown by the missense p.
Ala262Pro mutation carrier. Regarding the bone pheno-
type, the probands carrying deleterious mutations
showed a more severe bone phenotype of no statistical
significance, which was in agreement with other studies
that reported a trend between truncating mutations and
more severe skeletal phenotype [23,34,35]. However, no
conclusion can be obtained because patients from the
same family and with the same genotype showed bone
phenotype differences (data not shown) and on the
other hand, it is a subjective assessment made by differ-
ent physicians and not a quantitative variable. We are
aware that great caution should be exercised when
assessing genotype-phenotype correlation. In fact, phe-
notype variation between individuals with the same
Figure 3 Distribution of PHEX mutations recorded in the PHEX locus database [18]http://www.phexdb.mcgill.ca/(upper panel) and
distribution of mutations found in this study (lower panel).
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genotype, particularly regarding the skeletal phenotype,
is described [26,36].
To our knowledge, this is the largest study where a
correlation between biochemical phenotype and geno-
type was analyzed. There is a previous study with 8
patients about the genotype correlation with P, AP and
TRP which gave no positive results probably due to the
small sample size [35].
Regarding the intra-genotype variability, patients 21
and 22 both carry the c.1645C > T (p.Arg549X) muta-
tion and presented very similar phenotype except the
development of nephrocalcinosis after treatment.
Patients 32 and 33 carry the c.2104C > T (p.Arg702X)
mutation and also have similar phenotype except for the
development of hyper-PTH after treatment in one and
the height SDS unexpectedly positive in the other.
Regarding the intra-familial variability, the serum P
values and TRP were similar among carriers of the same
mutation whilst they showed greater skeletal variability
(Data not shown). Nevertheless, the number and size of
the families and the number of patients with recurrent
mutations was too small to get any conclusive data.
Hyperparathyroidism is rather frequently detected in
XLHR patients, which was traditionally explained by
chronic phosphorus therapy [37]. However, it should be
taken into account that disturbance of the PTH secre-
tion circadian rhythm has been reported among XLHR
patients, which increase in nocturnal pulses [38], In
addition, animal models of XLHR showed hyperpar-
athyroidism in the absence of treatment [39], and abun-
dant levels of PHEX mRNA were observed in the
parathyroid gland of two XLH patients [40]. In our
cohort, three patients presented hyperparathyroidism
before initiating medical therapy and eight more after
treatment. Ten of these patients had deleterious muta-
tions. All these data suggested that therapy with phos-
phorous is not the only cause of hyperparathyroidism in
XLHR patients and that more severe PHEX mutations
may have some influence.
A widespread concern is the occurrence of nephrocal-
cinosis in the medical treatment of XLHR patients,
nearly 80% in some reports. Several risk factors have
been identified for its pathogenesis: hypercalciuria,
hyperoxaluria and hyperphosphaturia [37]. In our opi-
nion, the degree of phosphaturia can be an important
risk factor because all patients in our cohort with
nephrocalcinosis had deleterious mutations which in
turn were those with less TRP and, therefore, greater
phosphaturia. Although the sample size was small and
the presence of nephrocalcinosis could be the result of
different treatment regimen, our data suggested that the
PHEX mutation type might be useful to detect patients
at increased risk of developing nephrocalcinosis.
Conclusion
In this report, the genetic analysis of a cohort of HR
patients as well as a genotype-phenotype correlation
study is presented. The putative PHEX mutation was
found in all the cases thus confirming genetically the
clinical diagnosis. Patients with deleterious mutations
presented lower TRP as well as lower 1,25(OH)2D serum
levels. They seem to be more at risk of developing hyper-
parathyroidism and nephrocalcinosis than patients with
likely causative mutations. Further studies with more
patients would be needed to confirm these results. The
highest density of mutations was observed in the third
last part of the gene. The mutational spectrum as well
the percentage of novel and de novo mutations was simi-
lar to previous reports. Our results confirmed XLHR in
all cases and allowed an adequate genetic counselling for
the families. We also performed the presymptomatic
diagnosis in individuals from affected pedigrees making it
possible for them to benefit from prompt therapy.
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